zanubrutinib
Selected indexed studies
- Zanubrutinib: past, present, and future. (Blood Cancer J, 2023) [PMID:37696810]
- Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. (Blood, 2024) [PMID:39316666]
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. (Lancet Oncol, 2022) [PMID:35810754]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Zanubrutinib: past, present, and future. (2023) pubmed
- Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. (2024) pubmed
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. (2022) pubmed
- Zanubrutinib. (2012) pubmed
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. (2023) pubmed
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2023) pubmed
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. (2025) pubmed
- Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. (2025) pubmed
- Zanubrutinib. (2006) pubmed
- Zanubrutinib: First Approval. (2020) pubmed